Fight HCC* with Optimized, High-Potency Y-90 Radiation
TheraSphere’s unmatched radioactive concentration starts with its unique physical characteristics. Y-90 is embedded within the glass matrix of each microsphere, providing a highly potent dose to arm you with a first-choice therapy to improve survivability and quality of life for patients with HCC liver cancer.
Glass Maintains a Higher Specific Activity Over Time
TheraSphere offers unrivaled power and flexibility, giving you optimal control and versatility to improve patient outcomes.
Personalized dosing. Simplified.
Simplicit90Y™ personalized dosimetry software, developed exclusively for TheraSphere Y-90 Glass Microspheres, allows you to enhance the consistency and efficiency of your dosing calculations. Visualize prospective dose distribution and assess the absorbed dose delivered to give you optimal versatility and control to calculate with confidence.
A Proven HCC Therapy for Improved Survivability and Outcomes
Key notable trials, DOSISPHERE-01 and TARGET confirmed the importance of optimal dosing and the correlation between high tumor response and overall survival benefit.
*Refers to HCC (Liver Cancer)
- Grosser OS, Ruf J, Pethe A, Kupitz D, Wissel H, Benckert C, Pech M, Ricke J, Amthauer H. Urinary Excretion of Yttrium-90 after Radioembolization with Yttrium-90-Labeled Resin-based Microspheres. Health Phys. 2018 Jan;114(1):58-63. doi: 10.1097/HP.0000000000000734. PMID: 29049048.
- TheraSphere™ Y-90 Glass Microspheres IFU. Data on file
- Sirtex SIR-Spheres® FLEXdose Delivery Program https://www.sirtex.com/media/168730/flexdose-brochure_singlpg-apm-us-018-07-20-v3.pdf
- SIR-Spheres® Y-90 Resin Microspheres IFU https://www.sirtex.com/ media/169247/ssl-us-14-sir-spheres-microspheres-ifu-us.pdf